RESULTS AND DISCUSSION

Age 59 years (33-81).

Median line of treatment: 4 (3-8).

Median of cycles received: 4 (2-13).

Drugs taken before: 72% capecitabine 56% gemcitabine 36% vinorelbine.

The median PFS was 2.7 months (8% patients censored, CI 95% 1.6-3.8) and the median OS was 10 months (40% patients censored, CI 95% 8.8-11.2).

MATERIALS AND METHODS

Observational retrospective study of 25 patients for three years (since August-2012 to August-2015) Dates: age, tolerance of eribulin, lines and cycles of treatment, progression-free survival (PFS) and OS.

CONCLUSIONS

PFS and OS (40% censored) were lower than in the clinical trial EMBRACE: 3.6 and 13.2 months respectively. Differences: sample size and patients more heavily treated in our case (maximum lines of treatment in the trial: 5).

Because of its easy administration and manageable toxicity eribulin is a good option in sequential monotherapy. Contemplating cost effectiveness, capcitabine should be consider first, according to the published studies.